Pre-clinical studies attest the potential of Hsp90 inhibition in inducing tumor growth inhibition, in reducing metastatic potential, and in sensibilizing tumors to the effect of other therapies, possibly as a consequence of the inhibition of DSBs repair and cell cycle checkpoint activation [23,33,35,53,54,55,56,57,58,59]. The gene discussed is HSP90AB1; the disease is neoplasm.